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Abstract
Withaferin A (WA) isolated from Withania somnifera (Ashwagandha) has recently become an attractive phytochemical under
investigation in various preclinical studies for treatment of different cancer types. In the present study, a comparative
pathway-based transcriptome analysis was applied in epithelial-like MCF-7 and triple negative mesenchymal MDA-MB-231
breast cancer cells exposed to different concentrations of WA which can be detected systemically in in vivo experiments.
Whereas WA treatment demonstrated attenuation of multiple cancer hallmarks, the withanolide analogue Withanone (WN)
did not exert any of the described effects at comparable concentrations. Pathway enrichment analysis revealed that WA
targets specific cancer processes related to cell death, cell cycle and proliferation, which could be functionally validated by
flow cytometry and real-time cell proliferation assays. WA also strongly decreased MDA-MB-231 invasion as determined by
single-cell collagen invasion assay. This was further supported by decreased gene expression of extracellular matrix-
degrading proteases (uPA, PLAT, ADAM8), cell adhesion molecules (integrins, laminins), pro-inflammatory mediators of the
metastasis-promoting tumor microenvironment (TNFSF12, IL6, ANGPTL2, CSF1R) and concomitant increased expression of
the validated breast cancer metastasis suppressor gene (BRMS1). In line with the transcriptional changes, nanomolar
concentrations of WA significantly decreased protein levels and corresponding activity of uPA in MDA-MB-231 cell
supernatant, further supporting its anti-metastatic properties. Finally, hierarchical clustering analysis of 84 chromatin writer-
reader-eraser enzymes revealed that WA treatment of invasive mesenchymal MDA-MB-231 cells reprogrammed their
transcription levels more similarly towards the pattern observed in non-invasive MCF-7 cells. In conclusion, taking into
account that sub-cytotoxic concentrations of WA target multiple metastatic effectors in therapy-resistant triple negative
breast cancer, WA-based therapeutic strategies targeting the uPA pathway hold promise for further (pre)clinical
development to defeat aggressive metastatic breast cancer.
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Introduction
Despite the tremendous advances made by screening programs
as well as a slight decrease in incidence in the last decade, breast
cancer remains the most frequently diagnosed cancer among
women in Western societies and the second leading cause of
cancer-related deaths worldwide [1]. Remarkably, the vast
majority of diagnosed breast cancers (85%) are neither linked to
genetic mutation of BRCA1 or BRCA2 genes nor to a family history
of such malignancy. Notwithstanding the existence of several
breast cancer chemotherapeutics, such as doxorubicine, paclitaxel,
or selective estrogen modulators (e.g. tamoxifen or raloxifene), the
latter remain highly ineffective in treating triple negative breast
cancers (TNBC), which are devoid of estrogen receptor, proges-
terone receptor and human epidermal growth factor receptor 2
(HER2/neu). These cancers form a heterogeneous group of the
most invasive cancers and remain the main obstacle in breast
cancer treatment [2,3]. Therefore, clinical development of
multifunctional therapeutics that would block the growth and
metastasis of transformed breast cells irrespective of their receptor
status, and that would be less cytotoxic to healthy, surrounding
cells than standard chemotherapeutics, is of great interest. Some
plant compounds and their secondary metabolites fulfill the
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abovementioned criteria. They exhibit strong anti-inflammatory
and anticancer effects while showing minor side effects, especially
during long-term exposure.
Withaferin A (WA), the main constituent of Withania somnifera
Dunal (also called Ashwagandha or Indian winter cherry), belongs
to the class of steroidal lactone metabolites (withanolides), which
play an important role in plant responses to pathogens, drought or
low temperature [4]. Various mechanisms have been proposed to
explain the anti-tumor activity of WA, including potent anti-
inflammatory, anti-angiogenic, anti-metastatic, pro-apoptotic and
radiosensitizing properties (reviewed in [5,6]). With respect to
breast cancer, WA and extracts of Withania somnifera were reported
to inhibit the viability and growth of several breast cancer cell lines
including ER-positive T-47D, MCF-7, MCF-7/BUS cells, and
triple negative MDA-MB-231, Sk-Br-3 cells [7] as well as MDA-
MB-231 human breast cancer xenografts in vivo [8]. Moreover,
recently WA’s efficacy in a mammary tumor virus-neu transgenic
mouse model was studied [9]. The underlying mechanism
responsible for anticancer properties of WA is not completely
understood, but recent studies have demonstrated that WA causes
G2/M cell cycle arrest or apoptosis via a FOXO3a- and BIM-
dependent mechanism, via inhibition of Hsp90 and via induction
of ROS production [8,10–12]. In metastatic breast cancer models,
WA has been shown to promote disassembly of vimentin, an
intermediate filament protein [13]. However, the specificity of this
interaction has recently been contested. Hence, effects of WA on
other intermediate filaments could also play a role [14]. Moreover,
Lee et al. have currently proposed that decreased breast cancer
cell migration following WA treatment might result from Notch
pathway activation [15]. Finally, we, and others, have shown that
WA inhibits constitutive and inducible activity of NF-kB and
FOSL1 (Fra1) in MDA-MB-231 cells [16,17]. These genes,
together with STAT3 and IL-6, mediate chronic inflammatory
responses in the tumor microenvironment, thus promoting
survival of malignant cells [18]. Since most published studies
focus on targeting breast cancer cell lines in general, irrespective of
their receptor expression status, the present study was undertaken
to identify key biological processes and novel molecular target
genes affected by WA in triple negative metastatic breast cancer
cells (MDA-MB-231) as compared to non-invasive ER-positive
MCF-7 cells. Moreover, to demonstrate WA’s specific effects, we
investigated the anticancer activity of another closely related
withanolide, Withanone (WN). In order to find unique cell line-
specific gene expression profiles we applied an integrated systems
biology approach by whole genome gene expression profiling
(Human HT-12 v4 BeadChip, Illumina) and subsequent Ingenuity
Pathway network analysis (IPA).
Results
WA decreases cell viability of cultured breast cancer cells
in a time- and concentration- dependent manner
In a first series of experiments, we assessed global cellular
cytotoxicity of WA at nM to mM concentrations in MCF-7 and
MDA-MB-231 cells. Cell death in breast cancer cells exposed to
different concentrations of WA or solvent for 24, 48 or 72 h was
determined by Gel Red staining and subsequent FACS analysis. A
time- and concentration-dependent decrease in cell viability was
revealed and expressed as decrease in Gel Red negative cell
fraction as shown in Figure 1A–B. To estimate the IC50
concentration at 72 hours we normalized cell viability from
100% in solvent control to 0% in the highest concentration of WA.
For 24 h and 48 h exposure, on the other hand, considerable
viability remained even at the highest WA concentrations.
Therefore IC50 values were not formally estimated. MCF-7 cells
revealed the highest sensitivity to WA treatment and an IC50 value
of 853.6 nM was estimated, with 95% CI ranging from 722.8 nM
to 1008.0 nM. MDA-MB-231 cells showed to be less sensitive to
WA treatment and an IC50 value of 1066 nM was estimated, with
95% CI ranging from 976.2 nM to 1164.0 nM (Figure 1C–D).
For further molecular studies and gene expression profiling in the
breast cancer cells, a sub-cytotoxic concentration of 700 nM was
selected, which is therapeutically relevant and effective in cancer
xenograft studies in vivo [13]. Furthermore, as low concentrations
of natural anticancer compounds can elicit stable changes in gene
expression through epigenetic mechanisms which are transmitted
through the cell cycle [19], WA was administered repeatedly,
every 24 h, to expose various cell generations.
Hierarchical clustering analysis of WA-responsive genes
identifies a highly reproducible set of breast cancer-
specific anticancer responses
RNA samples collected from non-invasive MCF-7 and triple
negative, metastatic MDA-MB-231 cells exposed for 72 hours to
WA or left untreated, were subjected to a genome-wide
transcriptome profiling. The R-package ‘‘Limma’’ (v3.14.1)
[20,21] identified 965 downregulated and 1145 upregulated genes
in MDA-MB-231 and a further 415 downregulated and 312
upregulated genes in MCF-7 cell line (including various transcript
variants). The heatmaps (Figure 2A) represent a graphical
presentation of WA-specific transcriptional changes in both cell
types in three biological replicates, revealing highly reproducible
and robust patterns of gene expression. Main biological processes,
specified by Ingenuity Pathway Analysis (IPA), are marked with
different colors and reveal common and cell type-specific
responses (Figure 2B). These are discussed in more detail in
the next paragraph.
WA affects four common and three cell type-specific
bioprocesses in non-invasive MCF-7 and triple negative,
metastatic MDA-MB-231 breast cancer cells
Differentially expressed genes (p,0.001; log2 ratio 1) were used
as an input for the core analysis in IPA. For genes represented by
multiple probes on the array (isoforms), the probe with the highest
fold change was selected reducing a total number of genes in the
analysis to 1580 and 499 in MDA-MB-231 and MCF-7 cells,
respectively. These genes, called focus genes, were overlaid onto a
global molecular network developed from information contained
in the Ingenuity knowledge base. Networks of the focus genes were
then algorithmically generated based on their connectivity. The
Bio Functional Analysis identified the biological functions and/or
diseases that were most significant to the data set. The top seven
bioprocesses affected by WA were selected for further investiga-
tion, of which four were common and three revealed a cell type-
specific WA response (Table 1; Figure 2B).
The proteins encoded by these genes are involved in cell growth
and proliferation, cancer progression, cell death and survival and
cell cycle regulation. All commonly regulated genes by WA are
presented in the heatmap (Figure S1). Next, three cell type-
specific WA-regulated processes, related to cellular movement,
gene expression and cellular development were identified by IPA
in triple negative MDA-MB-231 breast cancer cells. Inhibition of
target genes in these bioprocesses predicted that WA decreased
cell motility, invasion as well as epithelial-mesenchymal transition,
which are all key processes of breast cancer metastasis. In MCF-7,
on the other hand, cell type-specific bioprocesses included
regulation of many inflammatory, gastrointestinal cancer-related
Withaferin A Effects in Metastatic Breast Cancer
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genes (such as liver, colorectal, gallbladder cancers), cellular
assembly and organization as well as DNA replication, recombi-
nation and repair.
In addition, upon looking at the top predicted upstream
regulators of WA-responsive genes, we found nine common
regulators with consistently predicted altered activation state as
well as two transcription factors that were top-ranked in both cell
lines according to the p-value of overlap between their known
target genes and genes in the dataset (Table 2). They included
three cell cycle and cell proliferation controlling transcription
factors, among which two transcription activators, E2F1 and
FOXM1 are expected to be inhibited and one cyclin-dependent
kinase inhibitor 2A (CDKNA2A) to be activated by WA
treatment. Furthermore, we noted that WA administration is
predicted to activate two chromatin modifying enzymes: histone
demethylase JARID1B (KDM5B) and histone acetylase p300
(EP300) with transcriptional repressor and activator activity,
respectively. Finally, we looked at prediction of cell line-specific
transcription factor activation/inhibition. As shown in Table 2,
WA activation of the transcription factor SPDEF (SAM pointed
domain containing ETS transcription factor) shows the highest
relevance in MDA-MB-231 cells, a finding which is in line with the
inhibitory role of SPDEF in migration and invasion in several
types of cancer [22]. On the other hand, the prediction of the WA-
Figure 1. Effect of WA treatment on MDA-MB-231 and MCF-7 cell viability. (A–B) Dose-response curves of GelRedTM positive/negative
MDA-MB-231 and MCF-7 cells treated every 24 hours with increasing concentrations of WA for a total time of 24, 48 and 72 hours as determined by
FACS analysis. Data represent (mean 6 SEM) values of three independent experiments. Observed IC50 values for each time point are marked with a
dashed line. (C–D) Estimation of IC50 values at 72 hours exposure time was performed in GraphPad Prism version 5.00 for Windows using dose-
response curve fitting (log(inhibition) vs normalized response (variable slope)) of MDA-MB-231 and MCF-7 cells treated every 24 hours with different
doses of WA for a total time of 72 hours. Observations were normalized to a DMSO control, here represented as 100% viability.
doi:10.1371/journal.pone.0087850.g001
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dependent repression of Fra-1 (FOSL1) transcription factor, is in
line with our previous results [16] and the known role of Fra1 in
cell proliferation, motility and invasiveness of breast cancer cell
lines [23,24]. This further supports the hypothesis that effective-
ness of WA in triple negative breast cancer is mediated by
inhibition of cell motility and invasion programs.
Suppression of cell proliferation is WA-specific and
related to cell cycle arrest via E2F1- and KDM5B-
regulated molecular networks in both breast cancer cell
lines
Sustained proliferative signaling is one of the most fundamental
hallmarks of cancer. Thus, therapeutic compounds which block
unlimited release of growth factors are of high therapeutic interest
[25]. In this respect we performed a cell proliferation analysis
Figure 2. Biological processes affected by WA treatment in MDA-MB-231 and MCF-7 cells. (A) The heatmap represents gene expressions
for control and WA 700 nM treated MDA-MB-231 and MCF-7 cells. Only genes that have a log2 fold change (FC)$1 or #1 between control and WA-
treated samples and have a p-value,0.001 are plotted. Genes that are upregulated in treated samples are plotted above the dashed line (FC$1),
those that are downregulated in treated samples are plotted below (FC#1). Genes that belong to a specific IPA biological process are clustered and
represented by a colored square next to the heatmap. Color key legend represents log2 normalized expression values ranging from green (low
expression) to red (high expression). (B) Venn diagram represents common and cell line-specific IPA biological processes with predicted activation
state (Red arrow represents increase of a biological process- Activation Z-score$2; Green arrow represents decrease of a biological process-
Activation Z-score#-2).
doi:10.1371/journal.pone.0087850.g002
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using real-time, high-resolution xCELLigence technology. WA-
mediated effects on cellular proliferation are represented as
changes of average normalized cell indexes over time
(Figure 3A). Our results show a concentration-dependent
decrease in cell proliferation in both cell lines under the influence
of WA. Furthermore, in contrast to WN, WA inhibited the
proliferation of breast cancer cells at low nanomolar concentra-
tions, ranging from 175 to 700 nM. After 72-hour treatment,
concentrations as low as 175 nM decreased MDA-MB-231
proliferation by (29.3166.59)% and MCF-7 proliferation by
(29.7769.34)%. 700 nM WA almost completely abolished cell
proliferation resulting in (16.6661.52)% and (10.8363.79)%
proliferating MDA-MB-231 and MCF-7 cells, respectively. Next,
using IPA analysis we searched for the possible molecular target
genes responsive to WA, which could explain the above-described
decreased proliferation. A role for the CDK1/cyclin B1 complex
in WA-dependent growth inhibition and G2/M cell cycle arrest in
breast cancer cells has already been reported [11]. These results
are further supported by our transcriptome data of WA-treated
MCF-7 and MDA-MB-231 cells, which reveal decreased levels of
CDK1 mRNA level as well as lowered expression of CDK2 and
UHRF1, regulating both G1/S and G2/M cell cycle progression.
In addition, several genes encoding proteins essential for
replication initiation such as mini-chromosome maintenance
proteins (MCM3, MCM5, MCM6, MCM10), two DNA poly-
merases (POLA1, POLA2) as well as CDC45 and CDCA7 were
altered, suggesting that cell cycle arrest caused by WA is not
limited to G2/M phase arrest. Of special note, all abovementioned
genes are downstream targets of the E2F family of transcription
factors (Figure 3B), which was predicted earlier as one of the top
downregulated transcription regulators (Table 2) and experi-
mentally observed in ChIP-seq binding data in MCF-7 cell line
(Table S1; [26]). Furthermore, JARID1B histone demethylase
activated by WA treatment has been reported to associate with
E2F1 target genes to silence local chromatin accessibility by
removing H3K4 di- and trimethylation (Figure 3C). Similarly,
regulation of promoters of these genes by H3K4me2,me3 has
already been shown in ChIP experiments in human mammary
epithelial cells (HMEC) (Table S2; [26]).
For further evaluation of WA-specific effects on cell cycle
distribution, we performed flow cytometry after staining the cell
nuclei with propidium iodide. In line with our xCELLigence data,
we observed that only WA, but not WN, induced changes in cell
cycle distribution (Figure 3D). It was also clear that MCF-7 cells
were more sensitive to WA-induced cell cycle arrest. Even as low
as 175 nM of WA induced a significant increase in G2/M phase
(p,0.05) and a decrease in S phase (p,0.0001). Higher
concentrations of WA ranging from 350 to 700 nM caused a
further increase in G2/M fraction (p,0.0001) and decrease in S
and G0/G1 phase (p,0.0001). In contrast, MDA-MB-231 cells
exhibited significant cell cycle changes only at the highest
concentration of WA (700 nM), mainly related to an increase in
G2/M and a decrease in G0/G1 fraction (p,0.0001)
(Figure 3E).
WA, in contrast to WN, decreases invasiveness of MDA-
MB-231 breast cancer cells by targeting cell motility and
pro-inflammatory genes
Targeting metastasis in TNBC is one of the major focuses of
current oncology since no agents exist that effectively block
spreading of these highly invasive and often chemoresistant cells
[2]. By using a well-characterized in vitro model for TNBC (MDA-
MB-231) [27] we determined a subset of cell line-specific actors,
inhibited by WA treatment, known to be implicated in cell
adhesion, motility and invasion. Among them, we found genes
encoding for proteases involved in invasion promoting remodeling
of extracellular matrix, such as uPA (PLAU), ADAM metallopep-
tidases and cysteine proteinase- cathepsin B (CTSB), integrins
which promote cell survival and migration (ITGA6, ITGB4,
ITGB5, ITGAV) and several markers of epithelial-to-mesenchy-
mal transition (TGFA, TGFBR2, CDH11, S100A2, S100A4).
Some of these genes (PLAU, ITGA6) are known to be directly
repressed by the SPDEF transcription factor which was predicted
earlier as top activated transcription factor upon WA treatment
(Table 2). Additional repressed genes were ANGPTL2, TGM2,
IL-6, CSF1R, TNFSF12 as well as a key regulatory MAP kinase
ERK1/2 (MAPK3), all known to stimulate chronic inflammatory
signaling in the tumor microenvironment and to promote cancer
metastasis [28–32]. Finally, WA increased the expression of a well
established breast cancer metastasis suppressor 1 (BRMS1) [33]
(Figure 4).
These observations were further validated in an independent
experiment, to evaluate the mRNA expression of three selected
genes. These included urokinase plasminogen activator (PLAU) a
well characterized prognostic and predictive marker for breast
cancer invasion, the cell adhesion metallopeptidase ADAM8,
implicated in tumor-progressive degradation of ECM proteins,
Table 1. The top biological processes affected by WA in MCF-7 and MDA-MB-231 cells after 72-hour exposure to 700 nM WA.
Number of
molecules MCF-7 p-value Biological function MDA-MB-231 p-value Number of molecules
202 9.31E-18-6.62E-04 Cell Death and Survival 7.11E-34-3.31E-04 543
202 7.70E-22-6.55E-04 Cellular Growth and Proliferation 4.05E-28-3.17E-04 514
266 2.91E-39-6.55E-04 Cancer 7.14E-26-3.12E-04 591
158 4.81E-28-6.55E-04 Cell Cycle 1.82E-18-2.96E-04 237
Gene Expression 3.54E-20-2.13E-06 351
Cellular Movement 1.03E-18-3.05E-04 307
Cellular Development 2.67E-18-3.17E-04 215
150 2.20E-29-5.53E-04 Gastrointestinal cancers
118 4.29E-23-6.18E-04 Cellular Assembly and Organization
147 4.29E-23-6.55E-04 DNA Replication, recombination and repair
doi:10.1371/journal.pone.0087850.t001
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and a pro-inflammatory cytokine, TNFSF12. As shown in
Figure 5A, mRNA transcription of all these genes is elevated in
aggressive MDA-MB-231 cells, compared to their levels in MCF-7
cells, and decreased dose-dependently upon WA administration.
Suppression of uPA expression levels in WA-treated cells was
further corroborated by measurement of its activity. We first
investigated a direct inhibitory effect of WA on uPA proteolytic
activity using a Chemicon assay (Merck Millipore). Chromogenic
uPA substrate was incubated with 20U of uPA protein from
human urine in the absence or presence of DMSO, WN or WA at
several different concentrations. As shown in Figure 5B, neither
WA nor WN, caused direct inhibition of uPA activity. On the
contrary, uPA protein expression and activity in MDA-MB-231
cell-conditioned medium were decreased dose-dependently upon
Figure 3. Anti-proliferative activity of WA in MDA-MB-231 and MCF-7 cells is related to cell cycle arrest. (A) Real-time proliferation
curves as determined by xCELLigence RTCA. Changes in an average normalized cell index of MDA-MB-231 and MCF-7 cells left untreated or treated
with solvent control, WA or WN were monitored continuously for 96 hours (24 hours before treatment + 72 hours after treatment with the
compounds). Graphs represent mean values from three independent experiments starting at the time of the treatment. (B–C) Bar graphs represent
mean log2 fold change from three independent experiments of E2F1 and KDM5B target gene expressions of 700 nM WA-treated MDA-MB-231 and
MCF-7 cells relative to non-treated control samples as determined by Human HT-12 v4 BeadChip Gene Expression Array. (D) Analysis of the different
cell cycle phases was performed by flow cytometry following Vindelov labeling procedure with propidium iodide. Representative flow histograms of
MDA-MB-231 and MCF-7 cells treated for 72 hours with WA or WN compared to solvent control and untreated cells are presented. (E) Grouped bar
graphs represent quantification of different cell cycle phases by FlowJo software using Watson Pragmatic model. Data represent (mean 6 SEM)
values of three independent experiments.
doi:10.1371/journal.pone.0087850.g003
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WA treatment (Figure 5C–D). Of special note, this lowered
protein abundance was not related to the inhibition of secretion
because the intracellular levels of uPA remained very low (data not
shown). To functionally assess WA’s anti-invasive potential, we
studied the inhibition of formation of characteristic invasive
cellular extensions in the validated single-cell collagen invasion
model [34] (Figure S2). As depicted in Figure 5E, after 24 h
treatment only WA exposure abrogated MDA-MB-231 invasion
in a concentration-dependent manner, as compared to WN and
DMSO control. Significant differences with the solvent control
were reached as of 0.1 mM WA treatment. WN exposure,
however, lacked any significant effect related to anti-invasive
potential at concentrations ranging from 0.01 to 10 mM. These
results strongly implicate that by transcriptional suppression of
multiple genes involved in ECM remodeling, cell adhesion and
tumor-inflammation, WA specifically diminishes invasiveness of
MDA-MB-231 cells.
WA reprograms expression of chromatin writer-reader-
eraser enzymes
Because IPA analysis predicted JARID1B and p300 chromatin
enzymes as top transcriptional regulators of WA-responsive gene
expression, we wanted to explore whether WA changes expression
of additional chromatin-modifying enzymes. It is known that
deregulated or mutated chromatin enzymes and miswritten
epigenetic marks strongly contribute to cancer etiology [35] and
the therapeutic interest in modulation of these marks is growing.
In an independent set of experiments, we performed Human
Epigenetic Chromatin Modification Enzyme qPCR Array to
compare the expression of 84 well-known chromatin reader, writer
or eraser enzymes in both breast cancer cell types exposed to
solvent control or WA. The heatmap shown in Figure 6A
represents mean 22DCt values of gene expression of at least two
independent experiments compared to MDA-MB-231 control
sample. The highest concentration of WA (700 nM) triggered the
most pronounced changes in cofactor gene expression in MDA-
MB-231 cells (Figure S3), which after the treatment clustered
together with samples of MCF-7 epithelial-like phenotype
(Figure 6A). Besides modulation of SET domain proteins with
histone methyltransferase activity as well as histone ubiquitin
ligases, WA predominantly increased transcription of jumonji
domain enzymes. In the MCF-7 cell line, JARID1B (KDM5B) was
among two histone demethylases whose expression increased by
more than two-fold (Figure 6B). Other groups of chromatin
modifiers regulated in MCF-7 included Aurora kinases. In general,
the number of WA (up/down) regulated epigenetic cofactors in
MCF-7 cells was smaller than in MDA-MB-231 cells, implying
that the epigenetic plasticity of MCF-7 cells is more restricted than
in MDA-MB-231 cells. All transcripts which are significantly up-
or downregulated in either one or both cell lines upon 700 nM
WA treatment are listed in Table 3. In addition, Figure 6C
represents a comparison of basal levels of epigenetic modulators in
non-invasive MCF-7 and the highly aggressive MDA-MB-231
cells. Underlined genes (JMJD3, JMJD2C, NCOA3) change their
expression after WA administration in the direction towards the
less aggressive MCF-7 cell line, which may imply their role in
invasiveness or reflect the difference between cancer cells
originating from a primary tumor versus a metastatic tumor site.
Figure 4. Impact of WA on several essential steps of the metastatic cascade in MDA-MB-231 cells. Graphics is a modified version of
Figure 1 from [65]. Bar graphs represent mean log2 fold change from three independent experiments of metastasis target gene expressions of 700
nM WA-treated MDA-MB-231 and MCF-7 cells relative to non-treated control samples as determined by Human HT-12 v4 BeadChip Gene Expression
Array.
doi:10.1371/journal.pone.0087850.g004
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Figure 5. Decreased invasiveness of WA-treated MDA-MB-231 cells is associated with changed expression of ECM remodeling and
pro-inflammatory genes. (A) Effect of WA, WN on ADAM8, PLAU and TNFSF12 gene expression in MCF-7 and MDA-MB-231 cell lines normalized to
cyclophilin housekeeping gene and relative to DMSO-treated MCF-7 sample (2-DDCt) as determined by real-time quantitative PCR. Bar graphs
represent relative mRNA (mean 6 SEM) levels of three independent experiments. (B) Direct effect of WA, WN or DMSO on activity of uPA protein
from human urine. Bar graphs represent mean6 SEM uPA activity of two independent experiments (C) Effects of DMSO, WN or WA at three different
Withaferin A Effects in Metastatic Breast Cancer
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The exact interplay of multiple chromatin enzymes in pro/anti-
metastatic activities in breast cancer however requires further
investigation.
Discussion
The number of reports describing anticancer properties of WA
in vitro and more recently in vivo are rapidly growing [5,36]. Hence,
concentrations on uPA protein levels present in cell-conditioned medium was evaluated by Western blot. A representative blot picture of two
independent experiments is shown. (D) The enzymatic activity of uPA in the cell-conditioned medium of MCF-7 and MDA-MB-231 cells treated with
solvent, WA or WN as determined by CHEMICON colorimetric assay. Bar graphs represent mean 6 SEM uPA activity of three independent
experiments. (E) 24-hour collagen type-I invasion assay of MDA-MB-231 cells treated with DMSO, WA or WN. A box plot representing scored
normalized invasion indexes of two independent experiments is shown. Within the frame, statistical significance is indicated for comparisons of
treatment to the corresponding solvent condition. Above the frame, statistical significance is indicated for comparisons within a compound group.
doi:10.1371/journal.pone.0087850.g005
Figure 6. Modulation of chromatin writer-reader-eraser enzymes by WA in MDA-MB-231 and MCF-7 cells. (A) The heatmap represents
gene expressions of 84 known or predicted genes coding for chromatin-modifying enzymes and two housekeeping genes (ACTB, HPRT) for control
and WA-treated MDA-MB-231 and MCF-7 cells. Mean 22DCt values are compared pair-wise to MDA-MB-231 solvent control sample. The data represent
values from at least two independent experiments. Color key legend above the heatmap represents 22DCt normalized expression values ranging from
green (low expression) to red (high expression). (B) Bar graphs representing mean 22DCt normalized expression values of genes encoding for histone
demethyltransferases from at least two independent experiments. Fold changes between control (DMSO) and 700 nM WA-treated samples are
indicated above the corresponding bars. Significantly upregulated genes are marked with asterisks. (C) The scatter plot of the mean 22DCt
normalized expression values of each gene in the control sample (MDA-MB-231 DMSO) versus the test sample (MCF-7 DMSO). The most differentially
expressed genes are labeled next to the corresponding dot. WA-regulated genes are underlined. The black line indicates fold change 22DDCt of 1. The
dashed, gray lines indicate desired fold-change in gene expression threshold, here defined as 2.
doi:10.1371/journal.pone.0087850.g006
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a better understanding of its molecular mechanisms in cancer cells
is of primordial interest. Our data provide further insight into
multiple pathways targeted by WA in in vitro breast cancer cell
models with varying metastatic potential. Via microarray
transcriptome profiling of MCF-7 and MDA-MB-231 cells
exposed to systemic achievable concentrations of WA, we
identified common as well as cell line-specific target genes. In
the context of common cancer hallmarks affected by WA
treatment, we show here that the growth inhibitory potential of
WA is mediated mainly by cell cycle arrest. A real-time
xCELLigence proliferation assay as well as flow cytrometric cell
cycle analysis revealed a concentration- dependent decrease in cell
proliferation rate (Figure 3A), which correlated with an increased
cell population stalled in G2/M phase (Figures 3D–E) and
decreased cell viability in both cell lines (Figure 1A–D). Similarly
to Stan et al. we confirmed that WA decreased expression of
cyclin-dependent kinase 1 (CDK1), a regulator of G2/M transition
[11]. However, longer WA treatment resulted in additional
activation of cyclin-dependent kinase inhibitor 1A, which coin-
cided with downregulation of CDK2. In addition, numerous S
phase regulatory genes were also co-regulated in both cell lines,
but a significant decrease in S phase could only be detected in
MCF-7 cells (Table 1, Figure 2B, Figure 3E). We show here,
for the first time, that a remarkable number of cell cycle regulatory
genes modulated by WA in both cell lines represent E2F1 target
genes (Figure 3B). The E2F1-mediated regulation of these genes
was predicted by IPA analysis (Table 2) and further supported by
ChIP experiments in MCF-7 cells as specified by cSCAN analysis
(Table S1). However, further functional assays are required to
confirm the direct regulation of E2F1 transcription factor activity
by WA.
In addition, our study was designed to identify cell line-specific
regulators which could provide new mechanistic insights into
therapeutic strategies in highly aggressive, triple negative breast
cancer. We identified three cell line-specific processes regulated by
WA, of which the most pronounced was regulation of cell
movement. This category included genes related to cell motility,
extracellular matrix remodeling, adhesion and invasion, as
depicted in Figure 4. The multitude of WA targets as well as
the modulation of cytoskeleton and extracellular matrix proteins
suggested possible organism-wide debilitating effects of WA, as
previously proposed by Grin and colleagues [14]. Indeed, as
shown in our transcriptome analysis, WA modulates expression of
several genes involved in basic physiological processes. However,
when comparing expression data from both cell lines, it is
apparent that WA-mediated inhibition of integrins and laminins is
Table 3. Significantly differently expressed chromatin and DNA modifying enzymes as determined by Human Epigenetic
Chromatin Modification Enzyme qPCR Array.
MDA-MB-231 WA 700 nM/MDA-MB-
231 DMSO MCF-7 WA 700 nM/MCF-7 DMSO
Cofactor group Gene Fold change p-value Fold change p-value
DNA methyltransferases DNMT3B ns* ns 23.13 1.63E-03
Histone acetyltransferases CDYL 3.41 4.57E-02 ns ns
MYST2 4.54 3.22E-02 ns ns
NCOA3 7.65 2.33E-02 ns ns
ESCO2 ns ns 23.79 4.91e-03
Histone methyltransferases PRMT5 3.06 1.71E-02 ns ns
SMYD3 22.17 9.19E-04 ns ns
SET domain proteins
(Histone methyltransferase activity)
SETD2 2.57 2.59E-02 ns ns
SETD3 2.00 2.82E-02 ns ns
SETD4 4.52 1.16E-03 ns ns
SETDB2 3.60 1.05E-02 ns ns
SUV420H1 3.74 2.15E-02 ns ns
Histone demethyltransferases JARID1B 2.48 1.57E-02 2.47 1.14E-02
JMJD2C 6.36 9.15E-03 ns Ns
JMJD3 22.34 9.14E-03 ns Ns
MBD2 2.02 3.18E-02 ns Ns
Histone ubiquityn ligases MYSM1 3.41 8.30E-03 ns Ns
UBE2B 3.45 6.60E-03 ns Ns
USP16 2.35 3.37E-03 ns Ns
USP21 2.47 3.56E-02 ns Ns
Histone kinases AURKA ns ns 22.37 9.98E-03
AURKB ns ns 23.75 4.36E-02
AURKC 6.78 2.21E-02 4.60 1.71E-02
RPS6KA3 22.04 4.00E-02 ns Ns
*ns- not significant.
doi:10.1371/journal.pone.0087850.t003
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selective towards aggressive MDA-MB-231 cells. It has previously
been reported that aggressive breast cancers, despite the decreased
basement membrane deposition, constitutively overexpress some
laminins and integrin receptors which functionally contributes to
the motile and invasive phenotype of these cells. Consequently,
targeting their overexpression could be of great therapeutic
interest [37–40]. Of special note, the selective integrin antagonist
cilengitide has passed the Phase II clinical trials and is now being
tested in a Phase III trial in patients with glioblastoma [41].
Furthermore, WA caused concentration-dependent inhibition of
mRNA transcription of selected ECM-remodeling proteases
(ADAM8, ADAM10, CTSB and PLAT, uPA). The role of the
abovementioned genes in invasion and metastasis is well docu-
mented [33,42–44] and further supported by very high basal
expression of ADAM8, TNFSF12, PLAU genes in invasive MDA-
MB-231 cells as compared to non-invasive MCF-7 cells
(Figure 5A). The regulation of invasion-modulating genes by
WA but not by WN was mirrored by our single cell collagen
invasion assay as well as by uPA activity and protein detection
assays of MDA-MB-231 cells, in which we could show a clear anti-
invasive biological effect of WA but lack of effect for WN. Further
insight into the regulation of uPA revealed that WA reduced its
protein expression and activity via transcriptional control mech-
anism, as neither secretion nor the intrinsic activity were
abrogated by WA treatment (Figures 5B–E). Both uPA and
ADAM proteases are recognized as valuable biomarkers for
cancer prognosis and a number of selective inhibitors of these
proteins (INCB7839, INCB3619) [42,45,46] have revealed prom-
ising anti-tumor responses in phase I/II trials. The observation
that WA treatment downregulates mRNA expression of ADAM8
and uPA, and negatively affects uPA protein levels and enzymatic
activity, further strengthens the potential therapeutic effect of WA
in cancer therapy. Moreover, WA decreased epithelial-to-mesen-
chymal transition regulatory genes (Figure 4). In line with
Thaiparambil et al., we confirmed that invasion inhibiting doses of
WA after 24 h exposure were as low as 100 nM and not related to
cytotoxic effects. The same authors have shown that this initial
anti-invasive response may be related to vimentin ser56 phos-
phorylation and its perinuclear disassembly. However, short term
WA treatment did not result in significant changes in typical EMT
markers (E-cadherin, N-cadherin), leading the authors to conclude
that WA does not change the mesenchymal phenotype of MDA-
MB-231 cells [13]. On the contrary, in our experimental set up
WA decreased EMT-related components of the TGF-b signaling
pathway (TGFA, TGFBR2, CDH11 [47,48]), as well as TGM2,
HIF1A, several TNFSF family members and ANGPTL2, which
stimulate tumor promoting pro-inflammatory responses and a
hypoxic microenvironment. Inhibition of invasion was enforced by
upregulation of well characterized breast cancer metastasis
suppressor 1 (BRMS1), which was shown to regulate various steps
of the metastatic cascade including invasion, cell survival at
secondary sites and colonization of distant organs [33,49].
Finally, based on previous findings revealing chromatin-
dependent transcriptional regulation of IL-6 by WA in MDA-
MB-231 cells [16], we further explored the regulation of
chromatin writer-reader-eraser enzymes in WA-treated cells.
Nowadays, it is becoming clear, that misregulation of histone
modifications and DNA methylation catalyzed by these enzymes
actively contributes to human cancer, or in particular cancer cells
chemoresistance, proliferation and metastasis [35,50,51]. As such,
profiling of 84 known epigenetic enzymes in MDA-MB-231 and
MCF-7 cells exposed to three doses of WA as compared to solvent
control indeed revealed modulation of several classes of epigenetic
enzymes in both cell lines. However, MDA-MB-231 cells exposed
to 700 nM WA were subjected to the largest expression changes
upon WA treatment and clustered together with samples of MCF-
7 with a non-metastatic, epithelial-like phenotype as depicted in
the heatmap (Figure 6A). Moreover, having a closer look at
different classes of epigenetic modulators, we could confirm WA-
responsive regulation of JARID1B (KDM5B) in both cell lines,
involved in regulation of E2F1 target genes, in line with the
pathway analysis of our microarray data [52]. In MDA-MB-231
cells, we observed additional WA-specific upregulation of other
members of jumonji domain proteins, JMJD3 (KDM6B) and
JMJD2C (Figure 6B). However, conflicting data have been
published related to either tumor-promoting or -suppressing
activities of JARID1B, JMJD3 and JMJD2C, suggesting that the
overall effect in cancer may be context-dependent and rely on
concerted action of multiple epigenetic enzymes and/or combi-
natorial posttranslational modifications of nucleosomes and
transcription factors [53–59]. Finally, with exception of decreased
expression of DNMT3B in MCF-7 cells, we could not support a
major role for WA in changing expression of DNMTs, as recently
reported by Mirza et al [19]. Further studies need to clarify
whether WA can elicit stable gene specific DNA methylation
changes besides dynamic regulation of chromatin remodeling and
nucleosome accessibility.
In conclusion, the steroidal withanolide WA, isolated from
Withania somnifera (Ashwagandha) has become an increasingly
recognized phytomedicinal anticancer compound worldwide [6].
Despite intensive efforts and development of various chemother-
apeutic agents in the clinic, the efficacy of various therapies is still
limited by the heterogeneity of cancer cells and complex tumor-
stroma microenvironment interactions, which ultimately result in
clonal selection of a drug-resistant cell population [60]. In this
respect, natural medicinal compounds gained renewed interest as
chemotherapeutic agents to prevent or overcome therapy resis-
tance, due to their capacity to target multiple cancer hallmarks,
including proliferation, cell death resistance, replicative immor-
tality, invasion and metastasis, angiogenesis and tumor-promoting
inflammation [61,62]. By applying a pathway-based transcriptome
analysis of WA effects in non-aggressive versus triple negative
metastatic breast cancer cells, we identified various novel
molecular targets related to its anti-proliferative, anti-metastatic
and epigenetic mode of action. In summary, we demonstrate that
WA affects several clinically relevant targets in breast cancer cells
and have identified WA-dependent inhibition of the uPA pathway
as a novel mechanism underlying its potent anti-metastatic
activities. Remarkably, the closely related withanolide WN did
not reveal any anticancer or anti-metastatic activity at similar
concentrations. The efficacy of WA is clearly concentration-
dependent and attenuation of metastasis in MDA-MB-231 cells
could be observed at the lowest concentrations and might be
related to multifocal inhibition of signaling networks involving
ECM remodeling i.e. uPA signaling, pro-inflammatory tumor
cytokines and cell adhesion. Altogether, our results suggest that
WA based therapeutic strategies hold promise for further
(pre)clinical development to defeat aggressive metastatic breast
cancer.
Materials and Methods
Reagents
Withaferin A and Withanone (purity$97%, purchased from
Altavista Phytochemicals Pvt Ltd.) were dissolved in DMSO
(Hybri-Max, suitable for cell culture, Sigma-Aldrich, St. Louis,
MO, USA) to a stock solution of 20 mM and further diluted in
complete growth medium to a final concentration immediately
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before use. GelRedTM Nucleic Acid Stain in water (10 0006stock)
was purchased from Biotium (Hayward, CA, USA). DTT was
purchased from Sigma-Aldrich (St. Louis, MO, USA) and a stock
solution of 1 mM was prepared in water. Anti-uPA antibody (sc-
14019) was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
Cell lines and cell culture
The MDA-MB-231 and MCF-7 cell lines, purchased from
American Type Culture Collection (Manassas, VA, USA), were
cultivated in high glucose (4,5 g/L) Dulbecco’s Modified Eagle
Medium with 10% Fetal Bovine Serum, 2 mM L-Glutamine, 1
mM Sodium Pyruvate MEM, 50 IU/mL Penicillin and 50 mg/mL
Streptomycin. The MDA-MB-231 cell line was additionally
supplemented with 1% MEM Non-Essential Amino Acids. Each
cell line was maintained at 37uC in the humidified atmosphere
containing 5% CO2 until 80–90% confluence. Both cell lines have
successfully been authenticated by short tandem repeat (STR)
profiling (Cell ID System, Promega, Madison, WI, USA)
according to the manufacturer’s instructions. Prior to experiments
with WA or WN we evaluated cell growth properties, by means of
xCELLigence system (Roche, Penzberg, Germany), to determine the
optimal seeding density for a long-term experiment, which was 2 x
104 viable MDA-MB-231 cells/cm2 and 5,3 x 103 viable MCF-7
cells/cm2. Suitable amount of cells was plated in an appropriate
cell culture flask/plate 24 hours before the treatment. Every 24
hours, compounds or DMSO controls (final concentration
0,0035% if not otherwise stated) diluted in fresh medium were
added for a total time of 72 hours. At that time point, cells were
harvested with 0.05% Trypsin/EDTA solution, washed with 16
PBS and collected for further analysis. All cell culture reagents
were purchased from Life Technologies (Praisley, UK).
Flow cytometry
Cell viability. Cell viability was determined by flow cytom-
etry through addition of 16 GelRedTM Nucleic Acid Gel Stain
(Biotium, Hayward, CA, USA). MDA-MB-231 and MCF-7 cells
were plated in 24-well plates and treated with 6 different
concentrations of WA (0.0875, 0.175, 0.35, 0.7, 1.4, 2.8 mM) or
mock control (0.014% DMSO) as described above. After the
indicated time point, cell growth medium, PBS wash solution as
well as harvested cells were collected and centrifuged for 5 min at
250 x g. The cell pellet was resuspended in 1 mL of PBS
containing 5% FBS. For each concentration, three replicates were
performed and directly analyzed using an Epics XL-MCL
analytical flow cytometer (Beckman Coulter, Fullerton, CA,
USA). The mean value of at least three independent experiments
was calculated. IC50 concentrations were estimated for 72 h
treatments using GraphPad Prism version 5.00 for Windows,
modeling a dose response curve starting from 100% viability in
DMSO controls to 0% viability at the highest concentrations of
WA. The hill slope was not fixed.
Cell cycle analysis. Cell cycle distribution was assessed
according to the Vindelov method, as previously described [63].
After 72 hours treatment cells were harvested, washed with PBS
and two aliquots of approximately 1 x 106 cells were used for
subsequent staining procedure in each of three independent
experiments. Epics XL-MCL analytical flow cytometer (Beckman
Coulter, Fullerton, CA, USA) was used to measure the DNA
content and the data was analyzed in FlowJo software (Tree
Star, Inc., Ashland, OR, USA) using Watson pragmatic model.
One-way ANOVA with Tukey’s post test was performed using
GraphPad Prism version 5.00 for Windows (GraphPad Software,
La Jolla California, USA) to determine statistically significant
differences in the percentages of tumor cells in each cell cycle
phase (mean 6 SEM) between samples.
Real-time monitoring of cell proliferation using
xCELLigence (RTCA)
MDA-MB-231 and MCF-7 cell growth was continuously
monitored in 15 min intervals for a total time of 96 h using the
xCELLigence RTCA DP instrument (Roche). Background imped-
ance signal was measured following 30 min incubation with
100 mL of a suitable cell culture growth medium per well. The
final volume per well was adjusted to 150 mL by adding 50 mL of
cell culture suspension in a complete growth medium containing a
suitable amount of cells. 24 hours after seeding, DMSO control or
WA at 3 different concentrations (0.175, 0.35, 0.7 mM) were added
in a total volume of 150 mL. An additional control contained
untreated cells. For each concentration, two replicates on an E-
plate 16 were performed. The impedance signal was analyzed by
normalizing data of each well to the last measurement before the
compound treatment. CI(normalized) =CItime x/CInorm time. The
normalized cell indexes of three independent experiments were
used for graphical result representation and cell proliferation
measurement.
Invasion assay
Single cell collagen invasion assays were performed as
previously described [34]. In brief, MDA-MB-231 cells were
seeded on a collagen type-I matrix and treated with compounds or
solvent for 24 hours, after which the situation was documented via
phase-contrast microscopy using a Leica DMI3000B microscope,
a DFC 340 FX camera Twain version 7.4.0.0 and Leica
application Suit (LAS) v3.8.0 software. Invasiveness was scored
by assessing the protrusion of cellular extensions into the collagen
of at least 7 pictures per condition. The number of invasive cells
was normalized to the total number of cells and expressed as the
invasion index. Statistical analysis was performed, using a Mann
Whitney U test, showing significance of selected pair-wise
comparisons. Values of p,0.05 were considered significant.
RNA extraction and microarray processing
Total RNA from non-treated controls and WA-treated (700
nM) MDA-MB-231 and MCF-7 cells from three independent
experiments was isolated using 1 mL of TRI Reagent (Sigma-
Aldrich, St.Louis, MO, USA) per 5 x 106 cells and further
proceeded according to the manufacturer’s protocol till the step of
phase separation. After transferring the aqueous phase to a new
1.5 mL micro tube, an equal amount of 70% ethanol was added
and samples were further purified on RNeasy spin columns
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. Following extraction and concentration measurement
(NanoDrop 1000, Thermo Scientific, Waltham, MA, USA) total
RNA was quality controlled on a Bio-Rad experion (Bio-Rad,
Hercules, CA, USA). 500 ng of total RNA was amplified using the
Illumina TotalPrep RNA Amplification kit (Life Technologies,
Carlsbad, CA, USA). Briefly, RNA was reverse transcribed using
T7 oligo(dT) primers, after which biotinylated cRNA was
synthesized through an in vitro transcription reaction. 750 ng of
amplified cRNA was hybridized to a corresponding array of a
HumanHT12 beadchip (Illumina, San Diego, CA, USA). In total,
12 array hybridizations were performed. The beadchip was
incubated for 18 hours at 58uC in a hybridization oven under
continuous rocking. After several consecutive washing steps (see
manufacturer’s protocol), bead intensities were read on an
Illumina Iscan.
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Microarray data analysis
Raw data intensities were read in R using the ‘‘beadarray’’
package (v2.8.1) [64]. Intensities were quantile normalized and
differential gene expression between samples was estimated using
‘‘limma’’ (v3.14.1) [20,21]. Resulting p-values were corrected for
multiple hypothesis testing using the Benjamini Hochberg
procedure. Next to estimating gene expressions, euclidean
distances between samples were calculated and used as a distance
metric in a hierarchical cluster analysis.
Pathway analysis was performed in the Ingenuity Pathway
Knowledge Base (IngenuityH Systems, www.ingenuity.com, Red-
wood City, CA, USA) according to the instructions provided. A
fold change cut-off of 2 as well as false discovery rate of 0.1% were
set to identify genes whose expression was significantly differen-
tially regulated. The IPA automatically removed the duplicate or
unknown gene names from analysis resulting in lower number of
genes as compared to the total number of transcripts in the
microarray. Fischer’s exact test was used to calculate a p-value
determining the probability that each biological function and/or
disease assigned to that data set is due to chance alone. Raw array
data were uploaded to the Gene Expression Omnibus (GEO)
database and have accession number: GSE53049 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc =GSE53049).
Reverse transcription (RT)- PCR and real-time quantitative
PCR
1 mg of total RNA was reverse transcribed using oligo dT
primers (Life Technologies, Praisley, UK) and M-MLV Reverse
Transcriptase (Promega, MA, USA). Relative mRNA levels of
genes of interest were quantified by real-time quantitative PCR
reaction on ABI Prism 7300 (Applied Biosystems) and normalized
against cyclophilin housekeeping gene. Sequences of cDNA-
specific primers are available upon request. The 22DDCt method
was used for calculation of relative expression levels between
samples. Statistical analysis was performed using GraphPad Prism
version 5.00 for Windows (GraphPad Software, La Jolla Califor-
nia, USA). Relative gene expression values of three independent
experiments (mean 6 SEM) are represented on the bar graphs.
The bars in the graphs marked with different letters are
significantly different (p,0.0001 unless otherwise stated) as
determined by one-way ANOVA (Tukey Multiple Comparison
test).
Western blotting
MDA-MB-231 and MCF-7 cells were treated with WA, WN or
DMSO control as previously described. At the end of the
incubation time cell-conditioned medium was collected. Protein
concentrations were determined by the DC protein assay (Bio-
Rad, CA, USA). Samples from cell-conditioned media were
prepared by taking volume of supernatant with equal amount of
protein, addition of distilled water to final volume of 20 ml and
addition of 5 ml 56 Laemli sample buffer (300 nM Tris pH 6,8,
10% SDS, 50% glycerol, 0,05% Bromophenol Blue, 25% b-
mercaptoethanol). Proteins were separated on 8.5% SDS-PAGE,
and transferred onto a nitrocellulose membrane. Non-specific
binding sites on the membrane were blocked with a mixture of
50% Licor blocking buffer (Licor, Lincoln, NA, USA)/50% TBS
containing 0.2% Tween-20 for 1 hour. Afterwards membranes
were incubated with uPA recognizing primary antibody and
visualized with fluorophore-coupled secondary antibody. Addi-
tional loading control for samples from cell-conditioned media was
performed by staining the nitrocellulose membranes with 0,1%
ponceau red stain. Detection was performed by use of the Odyssey
Imaging System (Licor, Lincoln, NA, USA).
uPA enzyme activity assay
We examined the enzymatic activity of uPA in 160 mL of cell-
conditioned medium of the cells treated with solvent controls, WA
or WN at indicated concentrations, using the CHEMICON assay
(EMD Millipore, Merck, Darmstadt, Germany). This colorimetric
assay measures a cleavage of a chromogenic uPA substrate, which
results in a colored product, detectable by optical density at 405
nm. The standard curve was created by serial dilutions of known
amounts of uPA protein from human urine. Moreover, 20U of the
uPA protein was pre-incubated for 30 minutes with DMSO, WN
or different concentrations of WA to probe a direct inhibitory
effect of the compounds on uPA protein activity. Absorbance was
read on 2102 EnVision Multilabel Plate Reader (PerkinElmer,
Waltham, MA, USA) following 6 h 30 min incubation at 37uC.
One-way ANOVA with Tukey’s post test was performed to
determine statistically significant differences in the activity (mean
6 SEM) between samples.
Human Epigenetic Chromatin Modification Enzyme qPCR
Array
The Human Epigenetic Chromatin Modification Enzyme RT2
ProfilerTM PCR Array (PAHS-085A) (SABiosciences, Qiagen) was
used to determine the expression levels of 84 key genes coding for
chromatin modifying enzymes. 1 mg of total RNA, treated with
RNase-Free DNase Set (Qiagen), was used for further processing
according to the manufacturer’s protocol. cDNA synthesis was
performed by RT2 First Strand Kit (C-03). The RT2 SYBR Green
ROXTM qPCR Mastermix was used for preparing the experi-
mental cocktail according to the protocol and 25 mL was dispensed
to each well of 96-well PCR Array plate. Relative mRNA levels of
genes of interest were quantified by real-time quantitative PCR
reaction on an ABI Prism 7300 (Applied Biosystems, CA, USA)
and normalized against selected housekeeping genes (HPRT,
ACTB). An Excel-based RT2 Profiler PCR Array Template (V3.3)
(http://www.sabiosciences.com/pcrarraydataanalysis.php) was
used for statistical analysis (paired T-test) and fold change
quantification of the samples treated with WA as compared to
DMSO controls in both cell lines. A gene was considered not
detectable when Ct.35. Moreover, Ct was defined as 35 for the
DCt calculation when the signal was under detectable limits. Fold-
change and fold-regulation values.2 were indicative of upregu-
lated genes; fold-change values ,0.5 and fold-regulation values
,-2 were indicative of downregulated genes.
Supporting Information
Figure S1 WA target genes co-regulated in MCF-7 and
MDA-MB-231 cells. The heatmap represents the expression of
202 genes regulated by WA (Fold change $2, p,0.001) in a
highly consistent manner between MCF-7 and MDA-MB-231
cells. 114 genes are up-regulated and 85 genes are down-regulated
in both cell lines with only 3 commonly regulated genes showing
inconsistent regulation. Expression values are log transformed and
expressed as row z-score (difference between expression value and
average expression value of the gene divided by gene standard
deviation).
(TIF)
Figure S2 Representative phase-contrast microscopy
pictures depicting decreased MDA-MB-231 cell invasion
following WA, but not WN, treatment as determined by a
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24-hour collagen type-I invasion assay. The quantity of
solvent in ‘Solv’ was matched with the amount of DMSO in the
corresponding treatment. Invasive cells are indicated with white
arrows; non-invasive cells are indicated in the middle panel.
(TIF)
Figure S3 Concentration-dependent regulation of chro-
matin modifying enzyme gene expression by WA in
MDA-MB-231 and MCF-7 cells. The scatter plots of the mean
22DCt normalized expression values of each gene in the control
samples (MDA-MB-231 DMSO, MCF-7 DMSO) versus the test
samples (set-ups with WA) reveal the largest epigenetic plasticity of
MDA-MB-231 cells exposed to the highest WA concentration (700
nM). The black line indicates fold change 22DDCt of 1. The
dashed, gray lines indicate desired fold-change in gene expression
threshold, here defined as 2.
(TIF)
Table S1 A list of experimentally validated ChIP-
sequencing data for genes regulated by E2F1 transcrip-
tion factor in MCF-7 breast cancer cells.
(DOCX)
Table S2 A list of experimentally validated ChIP-
sequencing data for genes regulated by H3K4me2,me3
in Human Mammary Epithelial Cells (HMEC).
(DOCX)
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